Financial Performance - Revenue for the third quarter was 8,954,208,694 RMB, a 1.43% increase year-over-year[2] - Net profit attributable to shareholders for the third quarter was 3,076,337,561 RMB, a 9.31% decrease year-over-year[2] - Cumulative revenue from the beginning of the year to the end of the reporting period was 29,484,805,493 RMB, a 7.99% increase year-over-year[2] - Cumulative net profit attributable to shareholders from the beginning of the year to the end of the reporting period was 10,637,075,305 RMB, an 8.16% increase year-over-year[2] - Revenue for the first three quarters of 2024 reached 294.85 billion yuan, a year-on-year increase of 7.99%[12] - Net profit attributable to shareholders was 106.37 billion yuan, a year-on-year increase of 8.16%[12] - Total revenue for the current period reached 29.48 billion yuan, an increase from 27.30 billion yuan in the previous period[20] - Net profit attributable to the parent company increased to 28.58 billion yuan from 24.68 billion yuan in the previous period[19] - Net profit attributable to parent company shareholders reached RMB 10.637 billion, an increase from RMB 9.834 billion in the previous period[21] - Basic earnings per share increased to RMB 8.7808, up from RMB 8.1216 in the previous period[21] - Comprehensive income attributable to parent company shareholders was RMB 10.564 billion, compared to RMB 10.033 billion in the previous period[21] Cash Flow and Financial Position - Operating cash flow for the period increased by 42.50% year-over-year, reaching 11,072,880,996 RMB[2][6] - Total assets at the end of the reporting period were 57,601,486,436 RMB, a 20.15% increase compared to the end of the previous year[2] - Shareholders' equity attributable to the company at the end of the reporting period was 37,093,899,069 RMB, a 12.12% increase compared to the end of the previous year[2] - Total assets increased to 57.60 billion yuan from 47.94 billion yuan in the previous period[19] - Total liabilities increased to 15.59 billion yuan from 14.59 billion yuan in the previous period[18] - Total equity increased to 42.01 billion yuan from 33.35 billion yuan in the previous period[19] - Operating cash flow increased to RMB 11.073 billion, up from RMB 7.771 billion in the previous period[22] - Cash and cash equivalents at the end of the period decreased to RMB 15.583 billion from RMB 18.668 billion at the beginning of the period[23] - Tax refunds received increased to RMB 866.82 million, up from RMB 769.52 million in the previous period[22] - Payments for employee benefits and wages increased to RMB 6.429 billion, compared to RMB 5.649 billion in the previous period[22] Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period is 72,917[8] - Smartco Development Limited holds 26.98% of the shares, totaling 327,072,335 shares[8] - Magnifice (HK) Limited holds 24.49% of the shares, totaling 296,951,000 shares, with 36,820,000 shares pledged[8] - Hong Kong Securities Clearing Company Limited holds 12.01% of the shares, totaling 145,616,297 shares[8] - Ever Union (H.K.) Limited holds 4.25% of the shares, totaling 51,482,379 shares[8] - The China Industrial and Commercial Bank Limited - E Fund ChiNext ETF holds 1.20% of the shares, totaling 14,541,569 shares[8] - The China Industrial and Commercial Bank Limited - Huatai-PineBridge CSI 300 ETF holds 0.95% of the shares, totaling 11,520,049 shares[8] - Shenzhen Ruifu Management Consulting Partnership holds 0.86% of the shares, totaling 10,405,351 shares[8] - The China Industrial and Commercial Bank Limited - China Europe Healthcare Hybrid Fund holds 0.84% of the shares, totaling 10,183,344 shares[8] - Shenzhen Ruilong Consulting Services Partnership holds 0.84% of the shares, totaling 10,156,738 shares[8] Market and Product Performance - International market revenue grew by over 18%, with Europe and Asia-Pacific markets growing by more than 30%[12] - Domestic market revenue grew by less than 2% due to delayed hospital procurement and tight construction funds[12] - In vitro diagnostics product line grew by over 20%, with international in vitro diagnostics growing by over 30%[12] - Medical imaging product line grew by over 10%, driven by the Resona A20 ultrasound system[12] - Life information and support product line declined by over 10%, with domestic sales dropping by more than 20%[12] Research and Development - R&D investment in the first three quarters of 2024 was 28.43 billion yuan, accounting for 9.64% of revenue[13] - The company launched 10 new chemical luminescence immunoassay reagents and 10 biochemical analysis reagents in Q3 2024[13] - Cumulative patent applications reached 11,358, with 8,115 invention patents and 5,563 authorized patents[13] - R&D expenses increased to 2.59 billion yuan from 2.51 billion yuan in the previous period[20] Operational Costs and Liabilities - Operating costs for the current period were 17.87 billion yuan, up from 16.55 billion yuan in the previous period[20] - Inventory increased to 4.86 billion yuan from 3.98 billion yuan in the previous period[17] - Accounts receivable increased to 3.60 billion yuan from 3.30 billion yuan in the previous period[17] - Short-term borrowings decreased to 5.68 million yuan from 7.75 million yuan in the previous period[18] - Investment cash outflow was RMB 7.962 billion, a significant increase from RMB 5.910 billion in the previous period[22] - Financing cash outflow was RMB 6.969 billion, compared to RMB 5.593 billion in the previous period[23] Earnings and Shareholder Returns - Basic earnings per share for the third quarter were 2.5364 RMB, a 9.50% decrease year-over-year[2] - Weighted average return on equity for the third quarter was 7.93%, a decrease of 1.72 percentage points year-over-year[2] - Non-recurring gains and losses for the third quarter amounted to 19,324,724 RMB[4] - Sales revenue from goods and services reached RMB 31.578 billion, compared to RMB 26.496 billion in the previous period[22]

证券代码：300760 证券简称：迈瑞医疗 公告编号：2024-047 深圳迈瑞生物医疗电子股份有限公司 关于2024年第二次中期利润分配方案公告 二、董事会意见 公司董事会认为：公司综合考虑投资者的回报需求和公司的长远发展，在保证正常经 营业务发展的前提下拟定的2024年第二次中期利润分配方案符合公司实际情况，符合《公 司法》《公司章程》的规定。 三、监事会意见 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）于2024年5月17日召开2023 年年度股东大会，审议通过了《关于授权董事会制定中期分红方案的议案》，同意授权公 司董事会在符合利润分配的条件下制定具体的2024年中期分红方案。公司于2024年10月29 日召开第八届董事会第十次会议和第八届监事会第八次会议，审议通过了《关于2024年第 二次中期利润分配方案的议案》。现将相关事项公告如下： 一、利润分配方案基本情况 为积极响应监管号召、提高股东回报，公司推动一年多次分红，结合监管规则，以2023 年经审计的未分配利润为基准，合理考虑当期利润情况实施 ...

上述募集资金到位情况已由普华永道中天会计师事务所（特殊普通合伙）审验，并已 于2018年10月10日出具"普华永道中天验字(2018)第0626号"《验资报告》。公司已对募集资 金采取了专户存储，相关募集资金已全部存放于募集资金专户，并且公司及相关子公司与 存放募集资金的商业银行、保荐机构签订了《募集资金三方监管协议》《募集资金四方监管 协议》。 证券代码：300760 证券简称：迈瑞医疗 公告编号：2024-046 深圳迈瑞生物医疗电子股份有限公司 关于继续使用部分闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 为持续提高深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）及子公司资金利 用效率，继续合理利用闲置募集资金，优化经济效益，公司于2024年10月29日召开第八届董 事会第十次会议及第八届监事会第八次会议，审议通过了《关于继续使用部分闲置募集资 金进行现金管理的议案》，同意在确保募集资金安全和不影响公司正常经营的情况下，继续 使用闲置募集资金进行现金管理，购买安全性高、流动性好的存款类产品或保本型产品，包 括但不限于 ...

二、监事会会议审议情况 证券代码：300760 证券简称：迈瑞医疗 公告编号：2024-045 深圳迈瑞生物医疗电子股份有限公司 第八届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、监事会会议召开情况 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）第八届监事会第八次会议于 2024年10月29日在迈瑞总部大厦会议室以现场表决方式召开，会议通知于2024年10月25日 以电子邮件等方式送达全体监事。 会议由公司监事会主席汤志先生主持。本次会议应出席监事3人，实际到会监事3人。本 次会议的召集、召开符合《中华人民共和国公司法》和《深圳迈瑞生物医疗电子股份有限公 司章程》（以下简称"《公司章程》"）等有关规定。 经与会监事充分讨论，本次会议审议并通过了如下议案： 1、审议通过《关于<2024年第三季度报告>的议案》 经审议，监事会认为：董事会编制和审核《2024年第三季度报告》的程序符合法律、行 政法规、中国证监会和深圳证券交易所的规定，报告内容真实、准确、完整地反映了公司 2024年前三季度经营的实际情况，不存在任何虚假记载、 ...

核查意见 华泰联合证券有限责任公司 关于深圳迈瑞生物医疗电子股份有限公司 继续使用部分闲置募集资金进行现金管理的核查意见 为持续提高深圳迈瑞生物医疗电子股份有限公司（以下简称"迈瑞医疗"、 "上市公司"、"公司"）及子公司资金利用效率，继续合理利用闲置募集资金， 优化经济效益，公司于 2024 年 10 月 29 日召开第八届董事会第十次会议及第八 届监事会第八次会议，审议通过了《关于继续使用部分闲置募集资金进行现金管 理的议案》，同意在确保募集资金安全和不影响公司正常经营的情况下，继续使 用闲置募集资金进行现金管理，购买安全性高、流动性好的存款类产品或保本型 产品，包括但不限于大额存单、定期存款、结构性存款、通知存款、协定存款、 短期保本型产品等，使用期限自董事会审议通过之日起至 2025 年 10 月 31 日内 有效，有效期内业务实施总额不超过 6.37 亿元（含本数）。在上述额度及决议有 效期内，业务可循环滚动开展。 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐机构"）作 为迈瑞医疗首次公开发行股票并在创业板上市持续督导阶段的保荐机构，根据 《证券发行上市保荐业务管理办法》《上市公司监管 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2024-048 关于会计政策变更的公告 2、变更日期 公司自 2024 年 1 月 1 日起开始执行。 深圳迈瑞生物医疗电子股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 深圳迈瑞生物医疗电子股份有限公司（下称"公司"）本次会计政策变更是根据国家 统一的会计制度要求作出的变更，无需提交公司董事会和股东大会审议，对公司财务状况、 经营成果和现金流量无重大影响，不存在损害公司及全体股东利益的情形。 一、本次会计政策变更的概述 1、变更原因 2024 年 3 月，财政部会计司编写并发行了《企业会计准则应用指南汇编 2024》，其中 明确了企业因保证类质量保证产生的预计负债，应当按确定的金额，借记"主营业务成 本"、"其他业务成本"等科目，贷记"预计负债"科目。根据上述规定和要求，公司需 对原采用的相关会计政策进行相应变更。 二、本次会计政策变更对公司的影响 公司自 2024 年 1 月 1 日起执行《企业会计准则应用指南汇编 2024》中关于保证类质量 保证的会计处理规定，按确定的金额 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2024-044 深圳迈瑞生物医疗电子股份有限公司 第八届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）第八届董事会第十次会议于 2024年10月29日上午10:10在安徽砀山以现场加通讯表决相结合的方式召开，会议通知于 2024年10月25日以电子邮件等方式送达全体董事。 会议由公司董事长李西廷先生主持。本次会议应出席董事人数11人，实际出席董事人数 11人，其中董事徐航先生以通讯表决方式参会。本次会议的召集、召开符合《中华人民共和 国公司法》（以下简称"《公司法》"）和《深圳迈瑞生物医疗电子股份有限公司章程》（以下 简称"《公司章程》"）等有关规定。 二、董事会会议审议情况 经与会董事充分讨论，本次会议审议并通过了如下议案： 1、审议通过《关于<2024年第三季度报告>的议案》 经审议，董事会编制和审核的《2024年第三季度报告》，符合法律、行政法规、中国证 监会和深圳证券交易所的规定，报告内容真实、 ...

迈瑞医疗：第三季度净利润30.76亿元 同比下降9.31% 财联社10月29日电，迈瑞医疗发布2024年第三季 度报告，前三季度公司实现营业收入294.85亿元，同比增长7.99%；净利润106.37亿元，同比增长 8.16%。 其中，第三季度实现营业收入89.54亿元，同比增长1.43%；净利润30.76亿元，同比下降9.31%。 查看公告原文 ...

证券代码：300760 证券简称：迈瑞医疗 公告编号：2024-042 深圳迈瑞生物医疗电子股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）于近日接到公司控股股东 Magnifice（HK）Limited（以下简称"Magnifice（HK）"）的通知，获悉其将所持有的公司 部分股份办理了解除质押业务，现将具体内容公告如下： 一、 股东股份解除质押的基本情况 | | 是否为控 股股东或 | 本次解除质 | 占其所 | 占公司总 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 第一大股 | 押股份数量 | 持股份 | 股本比例 | 起始日 | | 解除日期 | | 质权人 | | | 东及其一 | （股） | 比例 | | | | | | | | | 致行动人 | | | | | | | | | | Magnifice | | | | | 202 ...

Market Performance and Growth - North America revenue CAGR from 2020-2023 was 16%, significantly higher than the low single-digit industry growth rate [2] - North America accounted for 6% of the company's H1 2024 revenue, with expectations for this proportion to continue declining [3] - Domestic equipment business contributed 27% of total revenue in H2 2023, with performance dependent on equipment renewal implementation [3] - Overseas revenue accounted for 41% of total revenue in H2 2023, expected to maintain rapid growth, especially in developing countries and Europe [3] Product and Market Strategy - The company has secured a three-year exclusive anesthesia machine supply agreement with the 10th largest IDN in the US [2] - Currently offering 3 product categories in the US market, with plans to expand from the existing 30 sub-product categories [3] - Achieved top 3 market share for key products in the US, including patient monitors, anesthesia machines, and POC ultrasound [2] - The company aims to enter the global top 20 medical device companies by 2025 [3] International Expansion - European market showing recovery, with breakthrough contracts at top hospitals including St Thomas' Hospital (UK), Charité - Universitätsmedizin Berlin (Germany), and Hôpital de la Pitié-Salpêtrière (France) [5] - Developing countries emerging as a major growth driver, with over one-third of revenue coming from IVD business [6] - Established localized production in 12 countries across major markets, with 9 facilities related to IVD production [6] AI and Technological Innovation - AI-powered blood cell morphology analyzer reduced average slide review time from 25-30 minutes to 30 seconds [6] - The MC series AI-powered blood cell analyzer has been installed in over 400 hospitals globally, surpassing competitor's decade-long sales within one year [7] - Collaborated with Tencent to develop a critical care domain model, currently being tested in top-tier Chinese hospitals [7] Policy and Market Environment - The Chinese government has allocated 300 billion RMB in ultra-long-term special treasury bonds to support medical equipment renewal [4] - Domestic equipment renewal projects have been approved, with hospital tendering processes expected to commence upon fund allocation [4] - The company has observed accelerated issuance of local government special bonds, supporting medical equipment procurement [3] M&A Strategy - The company has accelerated M&A activities since 2008, focusing on core technology enhancement, new business exploration, and overseas market expansion [4] - Recent M&A activities emphasize strengthening existing businesses and exploring new areas rather than merely expanding revenue [4] - Future M&A will focus on acquiring cutting-edge technologies and enhancing global R&D, marketing, and supply chain platforms [4]